FDA Brief

Warning letters Drugs

FDA warning letter to

FormPour

High riskIssued Mar 31Posted Apr 7Center for Drug Evaluation and Research (CDER)

FDA warned FormPour over selling an unapproved new drug, SMGT-GLT-1 Nano Microneedle Patch, on eBay.

What happened

FDA reviewed FormPour's eBay store in December 2025, not an inspection, and found the SMGT-GLT-1 Nano Microneedle Patch offered for sale in the United States. FDA says the labeling claims Type 2 diabetes treatment, weight loss, and cardiovascular protection and that the product is a new drug without an approved application.

What FDA found

  1. FormPour offered the SMGT-GLT-1 Nano Microneedle Patch for sale without an FDA-approved new drug application.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. FDA says introducing or delivering the product for interstate commerce violates the FD&C Act.

    sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  3. FDA says the product is a drug because its labeling claims it treats Type 2 diabetes, aids weight loss, and protects cardiovascular health.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  4. FDA says the product is not generally recognized as safe and effective for its labeled uses.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)

What FDA wants

FDA asks FormPour to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with supporting documents. If FormPour believes there is no violation, it must send its reasoning and evidence; if correction cannot be completed in time, it must explain the delay and give a completion date.

Who should pay attention

  • online sellers of health products
  • companies selling microneedle patches
  • businesses making diabetes or weight-loss claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk